Tigis

Psychiatrie supplementum 2/2019
Psychiatrie supplementum 2/2019

Psychiatrie supplementum 2/2019 (1)

úterý, 11 červen 2019 11:04

Psychiatrie Supplementum 2/2019

Napsal(a)

18. celostátní KONFERENCE BIOLOGICKÉ PSYCHIATRIE s mezinárodní účastí

Luhačovice 12.–15. června 2019

 

 

OBSAH

EDITORIAL ............................................................................................................................... 1

OBSAH ..................................................................................................................................... 2

PROGRAM ............................................................................................................................... 4

ODBORNÁ SYMPOZIA ............................................................................................................ 8
Kam cílí vývoj psychofarmak .................................................................................................... 8
Vliv meditace na biologii, strukturu a funkci mozku .................................................................. 8
Budou odhaleny příčiny duševních poruch? ............................................................................. 9
Reziduální příznaky depresivní poruchy a jejich význam v běžné klinické praxi .................... 11
Násilí a průběh psychózy ........................................................................................................ 12
Epidemiologická, ekonomická a klinická evidence péče o osoby s psychózami
v České republice ................................................................................................................... 13
Psychiatrická invalidita sedm let po první epizodě schizofrenie ............................................. 14
Nejvýznamnější nežádoucí účinky antipsychotik a jejich mechanismy .................................. 14
Význam nežádoucích účinků antipsychotik v klinické praxi .................................................... 15
Méně časté nežádoucí účinky antipsychotik .......................................................................... 16
Farmakovigilance v klinické praxi ........................................................................................... 17
Modulace předního cingula pomocí theta frekvenční vysokorozlišovací transkraniální
stimulace střídavým proudem (hd-tacs) – vliv na kontrolně inhibiční procesy ....................... 19
Vliv intenzivní transkraniální magnetické stimulace v léčbě negativních příznaků
schizofrenie a změna eeg mikrostavů .................................................................................... 20
Superagers neboli dlouhodobě kognitivně svěží osmdesátníci v ČR .................................... 22
Bipolární afektivní porucha a zánět ........................................................................................ 23
Plazmatický kortizol jako možný biomarker Alzheimerovy choroby ....................................... 23
Spektrální biomarkery Alzheimerovy choroby – projevy neurodegenerace
na úrovni plazmatických biomolekul ....................................................................................... 25
Metabolomika krevní plazmy jako účinný nástroj v diagnostice
Alzheimerovy choroby ............................................................................................................ 26
Oxid dusnatý v patogenéze psychických porúch ................................................................... 27
Psychóza, nebo úzkost? Kazuistika pacientky s Parkinsonovou nemocí .............................. 27
Kognitivní poruchy po anestezii a operaci .............................................................................. 28
Deliria na jednotkách intenzivní péče a možnosti jejich terapie ............................................. 29
Buněčná energetika jako cíl léčiv Alzheimerovy nemoci ....................................................... 30
Mitochondrie – méně známé skutečnosti .............................................................................. 32
Hologenom – úloha mikrobiomu ............................................................................................ 33
Bipolární porucha ve vyšším věku ......................................................................................... 34
Léčba poruch nálady ve vyšším věku: terapie neurostimulačními metodami ........................ 35
Léčba deprese ve vyšším věku ............................................................................................. 37
Léčba antidepresivy u demence ............................................................................................ 38

VÝVĚSKOVÁ SDĚLENÍ ......................................................................................................... 40

REJSTŘÍK .............................................................................................................................. 63

POKYNY AUTORŮM ............................................................................................................. 64

 

CONTENTS

EDITORIAL ............................................................................................................................. 1

CONTENTS  ........................................................................................................................... 2

PROGRAM ............................................................................................................................. 4
SCIENTIFIC SYMPOSIA ........................................................................................................ 8
Where development of new psychotropics is directed ............................................................ 8
The influence of meditation on biology, structure and function of the brain ............................ 8
Will causes of mental disorders be discovered? ..................................................................... 9
Residual symptoms in depressive disorders and their importance
in routine clinical practice ...................................................................................................... 11
Exposure to violence and outcome of psychosis .................................................................. 12
Epidemiologic, economic and clinical evidence on care for people with psychosis
in the czech republic ............................................................................................................. 13
Psychiatric disability seven years after the first episode of schizophrenia ............................ 14
The most significant side effects of antipsychotics and their mechanisms ............................ 14
Importance Of Antipsychotic Adverse Events In Clinical Practice ......................................... 15
Less frequent adverse-effects of antipsychotics .................................................................... 16
Pharmacovigilance in clinical practice ................................................................................... 17
Modulation of cingulate activity by theta frequency high-definition transcranial
alternating current stimulation (HD-tACS) – impact on control inhibition processes ............. 19
Influence of intensive transcranial magnetic stimulation in the treatment
of negative symptoms of schizophrenia and eeg microstate changes .................................. 20
Superagers in Czech republic ............................................................................................... 22
Bipolar affective disorder and inflammation ........................................................................... 23
Plasma cortisol as a possible biomarker of Alzheimer´s disease .......................................... 23
Spectral biomarkers of Alzheimer’s disease – manifestation of neurodegeneration
on the level of plasmatic biomolecules .................................................................................. 25
Metabolomics of blood plasma as an efficient tool in the diagnostics
of Alzheimer’s disease ........................................................................................................... 26
Nitric oxide in the pathogenesis of mental disorders ............................................................. 27
Psychosis or anxiety? A case-report of a patient with Parkinson’s disease .......................... 27
Cognitive disorders after anesthesia and surgery ................................................................. 28
Delirium at an intensive care unit and possible treatment attitudes ...................................... 29
Cellular energetics as the target of drugs of Alzheimer’s disease ........................................ 30
Mitochondria – the less known facts ..................................................................................... 32
Hologenom – The role of microbiom ..................................................................................... 33
Bipolar disorder in late-life ..................................................................................................... 34
Treatment of mood disorders in elderly: Treatment by neurostimulation methods ................ 35
The treatment of late-life depression ..................................................................................... 37
Antidepressant treatment in dementia  ...................................................................................38

POSTERS .............................................................................................................................. 40

INDEX .................................................................................................................................... 63

INSTRUCTIONS FOR AUTHORS ......................................................................................... 64